17.6 C
Munich
Wednesday, June 12, 2024

BMO upgrades Neurocrine to market perform on Ingrezza outlook (NBIX)

Must read

- Advertisement -


Unrecognizable female doctor holding graphic virtual visualization model of Brain organ in hands. Multiple virtual medical icons.

mi-viri/iStock via Getty Images

BMO Capital Markets has upgraded Neurocrine Biosciences (NASDAQ:NBIX) to market perform, citing its “improved confidence” in the “short-term durability” of the company’s neurological drug Ingrezza, also known as valbenazine.

The investment bank said the upgrade follows a survey of psychiatrists

- Advertisement -

- Advertisement -



Source link

- Advertisement -

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article